Concepedia

Donald Ludovici

DL

Statistics

Publications

11

Citations

1.5K

H-Index

11

Active since

1995

Affiliations

Janssen (United States)(Current)

Janssen (Belgium)

Rutgers, The State University of New Jersey

Springhouse

Johnson & Johnson (United States)

Donald Ludovici is an author at Janssen (United States) specializing in medicinal chemistry, pharmacology, and pharmacy.

Publications per year

1995–2018

11

Publications

11

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants

Kalyan Das, Arthur D. Clark, Paul Lewi et al. · Journal of Medicinal Chemistry · 2004 · 511 citations

, , +17

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans et al. · Antimicrobial Agents and Chemotherapy · 2004 · 322 citations · Full text

, , +17

Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues

Donald Ludovici, Bart L. De Corte, Michael J. Kukla et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 185 citations

, , +12

Evolution of Anti-HIV Drug CandidatesPart 2: Diaryltriazine (DATA) Analogues

Donald Ludovici, Robert W. Kavash, Michael J. Kukla et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 126 citations

, , +12

Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) Derivatives. 3

Henry J. Breslin, Michael J. Kukla, Donald Ludovici et al. · Journal of Medicinal Chemistry · 1995 · 97 citations

, , +6

1–5 of 11